このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

熱試験(Lutetium-177によるHER2抗体療法) (RAD202)

2026年9月21日 更新者:Radiopharm Theranostics, Ltd

177LU-RAD202の安全性と忍容性の第0/1研究、進行性固形腫瘍患者のヒト表皮成長因子受容体2に対するルテチウム-177放射標識単一ドメイン抗体2

This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

調査の概要

詳細な説明

This is a first-in-human, Phase 0/1, open-label study of 177Lu-RAD202 consisting of a Screening Period, a Treatment Period with 177Lu-RAD202 and a Safety and Long-Term Follow-Up Period to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Screening Period: Screening period of up to 4 weeks Phase I (Treatment Period): 177Lu-RAD202 dose escalation

  • Treatment Period with each cycle lasting 6 weeks. Extension of the planned dose intervals are possible following discussion and agreement between the Sponsor and Investigator.
  • Participants may be treated with multiple cycles as long as they appear to derive clinical benefit as determined by the Investigator and provided adequate clinical safety and organ dosimetry data.
  • DLT observation period for 177Lu-RAD202 is 6 weeks following first injection of 177Lu-RAD202.
  • Should an alternative treatment schedule be explored, the DLT observation period for 177Lu-RAD202 at that dose level will be the proposed cycle duration.

Safety Follow-Up Period:

  • An End of Treatment Visit performed within 7 days of the last dose of 177Lu-RAD202
  • A Safety Follow-up Visit performed every 12 ± 2 weeks from the End of Treatment Visit

研究の種類

介入

入学 (推定)

30

段階

  • 初期フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • New South Wales
      • Kingswood、New South Wales、オーストラリア、2747
      • Macquarie Park、New South Wales、オーストラリア、2109
      • Wollongong、New South Wales、オーストラリア、2500
    • Victoria
      • Fitzroy、Victoria、オーストラリア、3065
        • 募集
        • St Vincents Hospital, Melbourne
        • コンタクト:
    • Western Australia
      • Murdoch、Western Australia、オーストラリア、6150

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Aged 18 years and older.

  2. Written, voluntary, informed consent of the participants must be obtained in compliance with institutional, regional, and federal guidelines.

  3. Participants with histologically or cytologically confirmed, HER2 positive or HER2-low, advanced solid tumours that are relapsed/refractory, locally advanced not amenable to curative-intent therapy, or metastatic, with documented disease progression during or after their most recent line of anti-cancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.

    Participant HER2 positivity is determined by local testing and is defined as a score of 3+ on immunohistochemical analysis IHC), or, defined as a score of 2+ on IHC and positive results on in situ hybridisation (ISH). HER2-low is defined as a score of 1+ on IHC analysis or a score of 2+ on IHC analysis with ISH negative. If the participant tumor's HER2 status is unknown, it may be determined in a pre-screening step whereby the participant is asked to provide written informed consent to have their tumor tissue undergo IHC testing as determined by a validated test (tumor tissue may be obtained from archived samples or from a freshly obtained biopsy).

  4. Must have at least 1 measurable target lesion according to RECIST version 1.1.

  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

  6. Participants must have a life expectancy of ≥4 months in the opinion of the Investigator.

  7. Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

  8. WOCBP must agree to use a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  9. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. All male participants must agree to not donate sperm during the study and at least 90 days after the last dose of 177Lu-RAD202, whichever occurs later. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  10. Participants with previously treated brain metastases are eligible to participate if:

    1. They are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality [magnetic resonance imaging (MRI) or computed tomography (CT) scan] must be used for each assessment),
    2. Do not require corticosteroids to treat associated neurological symptoms, and
    3. Participants have no history of leptomeningeal disease or spinal cord compression.
    4. Participants with active brain metastases untreated with brain-directed therapy such as radiotherapy, are not eligible.

Exclusion Criteria:

  1. Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.

  2. Participants who have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time-point imaging procedures, etc.

  3. Residual toxicity Grade ≥ 2 from previously administered therapy (except for alopecia). Patients with Grade 2 or higher toxicity due to prior treatment may be allowed on a case-by-case basis in discussion with study Sponsor provided it is deemed not to put the participant at a higher risk of treatment-related toxicity or interfere with the integrity of study data, e.g., participants with endocrinopathy on stable replacement therapy

  4. Inadequate organ functions as reflected in laboratory parameters:

    • Creatinine clearance or Body Surface Area (BSA) adjusted Estimated glomerular filtration rate (eGFR) (calculated using any clinically validated formula, preferably Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or measured) < 60 mL/min
    • Platelet count of < 80 x 109/L
    • Absolute neutrophil count (ANC) < 1.5 x 109/L
    • Haemoglobin < 9 g/dL
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), or > 5 x ULN for participants with known liver metastases
    • Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN
    • For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≥ 1.5 or prothrombin time (PT) ≥ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≥1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR < 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
  5. Significant cardiovascular disease including:

    • Unstable angina and/or myocardial infarction within 6 months prior to screening
    • New York Heart Association Class II or greater congestive heart failure
    • Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)
    • QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome
    • Uncontrolled hypertension
    • Known LVEF < 50%. (LVEF may be performed either by echocardiogram or other appropriate imaging modalities such as nuclear cardiac imaging (MUGA) or MRI).
  6. History of uncontrolled allergic reactions and/or have hypersensitivity to anti-HER2 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity

  7. Pregnant or lactating women

  8. Participants who are receiving any other investigational agents

  9. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD202.

  10. Has had or is scheduled to have major surgery ≤ 28 days prior to the first dose of 177Lu-RAD202. Surgical procedures not considered to put participants at higher risk of AEs and/or interfere with the integrity of study outcome may be allowed on a case-by-case basis in discussion with the Sponsor.

  11. Positive status for human immunodeficiency virus (HIV).

  12. Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.

  13. Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.

  14. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:177Lu-RAD202

Single-arm, open-label study of 177Lu-RAD202

177Lu-RAD202 administered at treatment doses

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety and tolerability of 177Lu-RAD202
時間枠:6 weeks

The properties, incidence, nature and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

6 weeks
Recommended dose(s) of 177Lu-RAD202 for future exploration
時間枠:6 weeks

Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD202 injection cycle of treatment

6 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Preliminary antitumor activity of 177Lu-RAD202
時間枠:Up to 30 weeks

Objective response rates (ORR) as assessed by RECIST v1.1

Up to 30 weeks
Time Activity Curves (TACs)
時間枠:72 hours

Percent of the injected activity vs time for selected organs and tumors

72 hours
Radiation dosimetry of 177Lu-RAD202
時間枠:72 hours

Absorbed radiation doses of 177Lu-RAD202tr in critical organs (e.g., kidneys, bone marrow)

72 hours
Pharmacokinetics of 177Lu-RAD202
時間枠:72 hours

Half-life of 177Lu-RAD202 in blood

72 hours
Biokinetics of 177Lu-RAD202
時間枠:72 hours

Time-integrated activity coefficients of 177Lu-RAD202 in organs and tumor lesions

72 hours

その他の成果指標

結果測定
メジャーの説明
時間枠
To explore the use of SPECT/CT as a measure of preliminary anti-tumor activity of 177Lu-RAD202
時間枠:Up to 30 weeks

Longitudinal assessments of quantitative tumor uptake of 177Lu-RAD202 using SPECT/CT

Up to 30 weeks
To study the effect of amino acid infusion on 177Lu-RAD202 radiation absorption
時間枠:Up to 30 weeks

Absorbed radiation doses of 177Lu-RAD202 in critical organs (e.g. kidneys, bone marrow)

Up to 30 weeks
Level of agreement between 177Lu-RAD202 and standard of care imaging
時間枠:Up to 30 weeks

Standard of care imaging may include but is not limited to 18F-FDG-PET, CT-scan and/or 99mTc-MDP-bone

Up to 30 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年2月12日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2025年2月7日

QC基準を満たした最初の提出物

2025年2月7日

最初の投稿 (実際)

2025年2月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • RAD202.2022.0002

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する